These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24395322)

  • 1. Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement.
    Bloch BV; Patel V; Best AJ
    Bone Joint J; 2014 Jan; 96-B(1):122-6. PubMed ID: 24395322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
    Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty.
    Mommsen P; Doering M; R O Hrs E; Egidy C; Gehrke T; Krettek C; Kendoff D
    Technol Health Care; 2014; 22(6):901-8. PubMed ID: 25318954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
    Cohen A; Drost P; Marchant N; Mitchell S; Orme M; Rublee D; Simon TA; Sutton A
    Clin Appl Thromb Hemost; 2012 Nov; 18(6):611-27. PubMed ID: 22387582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran.
    Murphy L; Lawler L; Kavanagh EC
    AJNR Am J Neuroradiol; 2011; 32(10):E195. PubMed ID: 22084193
    [No Abstract]   [Full Text] [Related]  

  • 7. Wound problems following hip arthroplasty before and after the introduction of a direct thrombin inhibitor for thromboprophylaxis.
    Gill SK; Theodorides A; Smith N; Maguire E; Whitehouse SL; Rigby MC; Ivory JP
    Hip Int; 2011; 21(6):678-83. PubMed ID: 22117258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV; Quinlan DJ; Dahl OE; Schulman S
    Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct thrombin inhibitor (DTI) vs. aspirin in primary total hip and knee replacement using wound ooze as the primary outcome measure. A prospective cohort study.
    Aquilina AL; Brunton LR; Whitehouse MR; Sullivan N; Blom AW
    Hip Int; 2012; 22(1):22-7. PubMed ID: 22362503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
    Samama CM; Rosencher N; Kleine E; Feuring M; Brueckmann M; Clemens A; Gullberg J; Frostick SP
    Thromb Res; 2016 Jul; 143():103-10. PubMed ID: 27208980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
    Eriksson BI; Dahl OE; Feuring M; Clemens A; Noack H; Hantel S; Friedman RJ; Huo M
    Thromb Res; 2012 Nov; 130(5):818-20. PubMed ID: 22840686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
    Dahl OE; Kurth AA; Rosencher N; Noack H; Clemens A; Eriksson BI
    Int Orthop; 2012 Apr; 36(4):741-8. PubMed ID: 22095136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study].
    Peidro-Garcés L; Otero-Fernandez R; Lozano-Lizarraga L
    Rev Esp Cir Ortop Traumatol; 2013; 57(1):53-60. PubMed ID: 23594983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
    Fisher WD
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S15-21. PubMed ID: 21517651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.
    Gionis MN; Ioannou CV; Katsamouris AN; Katonis P; Balalis K; Sfyridaki K; Elalamy I; Gerotziafas GT
    Thromb Res; 2013; 132(6):685-91. PubMed ID: 24182549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran vs. low molecular weight heparin in preventing venous thromboembolism after elective hip and knee arthroplasty: evaluation of selected clinical parameters.
    Mrozik D; Jackiewicz A; Krzemiński M
    Pol Orthop Traumatol; 2012 Oct; 77():111-4. PubMed ID: 23306297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data.
    Jameson SS; Baker PN; Charman SC; Deehan DJ; Reed MR; Gregg PJ; Van der Meulen JH
    J Bone Joint Surg Br; 2012 Jul; 94(7):914-8. PubMed ID: 22733945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry.
    Jameson SS; Charman SC; Gregg PJ; Reed MR; van der Meulen JH
    J Bone Joint Surg Br; 2011 Nov; 93(11):1465-70. PubMed ID: 22058295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA; Espada NG; Merino RG; González TC
    Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty.
    Gombár C; Horvath G; Gálity H; Sisák K; Tóth K
    Arch Orthop Trauma Surg; 2014 Apr; 134(4):449-57. PubMed ID: 24488447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.